Costs to cut risk of sickle cell disease beyond reach of most in India: Lancet Commission
The HinduThe costs required to reduce the risk of sickle cell disease are beyond the reach of most individuals in India and sub-Saharan Africa, where the disease is most prevalent, says a new Commission published in The Lancet Haematology journal. The Commission publishes shortly after a recent study in the same journal found that the highest burden of sickle cell disease disability was concentrated in western and central sub-Saharan Africa and India. “Whereas the majority of major causes of death are decreasing, the number of deaths due to sickle cell disease is increasing globally," said chair of the Commission, Frederic Piel from Imperial College London, U.K. "The costs required to reduce the risk of sickle cell disease is beyond the reach of most individuals in sub-Saharan Africa and India where the disease is most prevalent - it needs to be directly funded by governments," said Mr. Piel. "With adequate engagement of governments, the changes identified in our Commission are achievable and will improve the lives of people with sickle cell disease throughout the world," Mr. Piel added.